Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting-Reference-Cited by-同舟云学术

Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting

Published:2022-07-11 Issue:9 Volume:35 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Megna Matteo¹^ORCID,Potestio Luca¹^ORCID,Camela Elisa¹^ORCID,Fabbrocini Gabriella¹^ORCID,Ruggiero Angelo¹^ORCID

Affiliation:

1. Section of Dermatology, Department of Clinical Medicine and Surgery University of Naples Federico II Naples Italy

Publisher

Hindawi Limited

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.15667

Reference59 articles.

1. Psoriasis Pathogenesis and Treatment

2. Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice

3. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis

4. Current guidelines for psoriasis treatment: a work in progress;Golbari NM;Cutis,2018

5. Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Data on Brodalumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: An Observational Study from the Czech Republic BIOREP Registry;Advances in Therapy;2024-08-29

2. Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis;Expert Opinion on Drug Safety;2024-08-17

3. Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry;Drugs - Real World Outcomes;2024-06-24

4. Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond;Expert Opinion on Pharmacotherapy;2024-06-12

5. Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation;Expert Opinion on Drug Safety;2024-05-06